Pfizer's monthly obesity drug, berobenatide, acquired from Metsera, has shown promising results in a mid-stage study, with patients losing up to 12.1% of their weight over 28 weeks. However, its competitiveness against existing weekly injectable treatments remains uncertain, as the weight loss observed is still less than that seen with similar drugs on the market.
Pfizer's obesity drug, berobenatide, demonstrates continued weight loss when transitioned from weekly to monthly dosing, indicating potential for less frequent administration without a loss in efficacy. However, it remains to be seen how it will compete with Eli Lilly’s Zepbound, which has shown superior weight loss results in similar timeframes. For someone tracking competitive landscapes in pharma, particularly in weight management, these dynamics could inform investment or partnership decisions.